Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089.
Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089.
复制标题
司他夫定治疗艾滋病和艾滋病相关综合症患者:艾滋病临床试验组 089。
DOI:
10.1093/infdis/171.supplement_2.s123
复制
发表时间:
1995
期刊:
影响因子:
--
通讯作者:
Dunkle,LM
中科院分区:
文献类型:
--
作者:
Murray,HW;Squires,KE;Weiss,W;Sledz,S;Sacks,HS;Hassett,J;Cross,A;Anderson,RE;Dunkle,LM
In a phase I trial of stavudine in AIDS or AIDS-related complex (ARC), antiviral effects and safety were assessed in 41 patients treated with dosages of 0.5–12.0 mg/kg/day. Among evaluable patients, 10% increases in CD4lymphocyte counts were sustained in 24 (60%) of 40 during treatment; anNAVCresponse (normalized area under the CD4 cell count-versus-time curve > 1.0) was observed in 31 (91 %) of 34 at 10 weeks and in 20 (80%) of 25 at 24 weeks; 15 (83%) of 18 had decreases in p24 antigenemia; and 24 (60%) of 40 gained >2.5 kg body weight. Median CD4lymphocyte levels remained above baseline for 6 months in patients receiving >0.5 rug/kg/day. Median serum p24 antigen levels remained below baseline for >1 year in patients with p24 antigen responses. The principal toxicity was peripheral neuropathy, which generally resolved after drug discontinuation but limited the dosage to <2.0 rug/kg/day. Additional trials assessing the effect of stavudine on overall morbidity and mortality are ongoing.
登录
查看更多内容
DOI:
10.1016/s0021-9258(18)83322-1
发表时间:
1989-04
期刊:
The Journal of biological chemistry
影响因子:
--
作者:
J. Balzarini;P. Herdewijn;E. Clercq
通讯作者:
J. Balzarini;P. Herdewijn;E. Clercq
DOI:
--
发表时间:
1987
期刊:
影响因子:
--
作者:
E. Matthes;C. Lehmann;D. Scholz;M. Janta;K. Gaertner;H. Rosenthal;P. Langen
通讯作者:
P. Langen
DOI:
10.1073/pnas.83.21.8333
发表时间:
1986-11-01
影响因子:
11.1
作者:
FURMAN, PA;FYFE, JA;BARRY, DW
通讯作者:
BARRY, DW
影响因子:
5.8
作者:
Zhu,Z;Ho,HT;Hitchcock,MJ;Sommadossi,JP
通讯作者:
Sommadossi,JP
影响因子:
7.3
作者:
MANSURI, MM;STARRETT, JE;MARTIN, JC
通讯作者:
MARTIN, JC